Actively Recruiting
Evaluating BCMA-Targeted Prime CAR-T Cell Therapy for Relapsed or Refractory Multiple Myeloma and Plasma Cell Disease
Led by Chongqing Precision Biotech Co., Ltd · Updated on 2025-02-25
80
Participants Needed
1
Research Sites
26 weeks
Total Duration
AI-Summary
What this Trial Is About
Researchers are evaluating the safety and effectiveness of BCMA-targeted prime CAR-T cell therapy in patients with relapsed or refractory Multiple Myeloma and other plasma cell diseases. This study focuses on patients who have limited treatment options and aims to assess adverse events and disease response after receiving this targeted therapy. Participants will receive a single treatment of BCMA-targeted prime CAR-T cells designed to attack myeloma cells expressing BCMA. The study includes Phase 1 and Phase 2 components and monitors patients for up to two years to evaluate treatment response and safety. During the study, participants will undergo regular assessments including monitoring of adverse events, disease status, levels of BCMA-targeted CAR-T cells in blood and bone marrow, clonal plasma cell quantities, serum IL-6 levels, and survival outcomes. The total follow-up duration for outcome measurement is up to two years to observe treatment effects and patient safety over time.
CONDITIONS
Brief Title
a Clinical Research of BCMA-Targeted Prime CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease
Research Team
Z
Zhi Yang, PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
